[CME/CPE Cat 3A: Allergy & Immunology, Dermatology] Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks

CME points will be awarded to doctors who submit claims for reading papers from Refereed Journals recommended by SMC or listed in PubMed. Papers must be published within the last 2 years. Claims from other publications, such as newsletters, magazines or non-refereed journals, will be rejected. This article serves as a concise overview of the key insights extracted from the original article. Hence, ensure to cite the actual research paper in your CME Cat. 3A claim. Link to the paper is provided in the footnotes. For more information, visit: [Criteria], [List]

CPE points will be award to pharmacists who submit claims for reading papers from the list of journals recommended by the SPC if they wish to minimise the rejection of claims for reading non-recognised materials. This article serves as a concise overview of the key insights extracted from the original article. Hence, ensure to cite the actual research paper in your CPE Cat. 3A claim. Link to the paper is provided in the footnotes. For more information, visit: [Main], [Guide, Page 26], [List]